10 Speculative Biotech and Biohealth Stocks With Massive Analyst Upside Calls

Health and Healthcare

Published: May 23, 2016 8:05 am

Last Updated: January 13, 2020 7:43 am

Investors have had a hard time in May. Biotech investors also have faced some hard decisions going into the 2016 elections, where both sides of the aisle seem more than willing to attack pharmaceutical companies for how they price drugs.

What is interesting here is that biotech is the one sector that still offers massive upside for investors — if they can pick the right companies that is. The biotechs are the one group that could one day create a cure or perfect ways to treat cancer, heart issues, diabetes and just about every nasty disease and ailment you can think of. That means they could have unlimited upside — but any savvy investor knows that this also comes with extreme risk.

24/7 Wall St. tracks many analyst upgrades and downgrades each day of the week. This turns out to be hundreds each week. Many biotech and biohealth stocks end up standing out above the rest of the pack because they often come with upside price targets that may be too good to be true.